These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1648432)

  • 1. Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11.
    Curran WJ; Cox JD; Azarnia N; Byhardt RW; Shin KH; Emani B; Phillips TL; Selim H; Herskovic A; Mohiuddin M
    Cancer; 1991 Aug; 68(3):509-16. PubMed ID: 1648432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
    Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
    J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of radiologic stage III substage on nonsurgical therapy of non-small cell lung cancer.
    Kreisman H; Lisbona A; Olson L; Propert KJ; Modeas C; Dillman RO; Seagren SL; Green MR
    Cancer; 1993 Sep; 72(5):1588-96. PubMed ID: 8394201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
    Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Pajak TF
    J Clin Oncol; 1990 Sep; 8(9):1543-55. PubMed ID: 2167952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC).
    Komaki R; Scott CB; Byhardt R; Emami B; Asbell SO; Russell AH; Roach M; Parliament MB; Gaspar LE
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):263-7. PubMed ID: 9788403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.
    Firat S; Byhardt RW; Gore E
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.
    Werner-Wasik M; Scott C; Cox JD; Sause WT; Byhardt RW; Asbell S; Russell A; Komaki R; Lee JS
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1475-82. PubMed ID: 11121651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08.
    Cox JD; Pajak TF; Herskovic A; Urtasun R; Podolsky WJ; Seydel HG
    Am J Clin Oncol; 1991 Aug; 14(4):280-4. PubMed ID: 1650526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04).
    Bradley JD; Scott CB; Paris KJ; Demas WF; Machtay M; Komaki R; Movsas B; Rubin P; Sause WT
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1173-9. PubMed ID: 11955727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small-cell lung cancer treated with radiation therapy.
    Curran WJ; Stafford PM
    J Clin Oncol; 1990 Mar; 8(3):409-15. PubMed ID: 2155312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: Analysis of the Radiation Therapy Oncology Group experience.
    Machtay M; Seiferheld W; Komaki R; Cox JD; Sause WT; Byhardt RW
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):847-53. PubMed ID: 10386642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease).
    Rosenthal SA; Curran WJ; Herbert SH; Hughes EN; Sandler HM; Stafford PM; McKenna WG
    Cancer; 1992 Nov; 70(10):2410-7. PubMed ID: 1330280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of comorbidity and age on RTOG study enrollment in Stage III non-small cell lung cancer patients who are eligible for RTOG studies.
    Firat S; Byhardt RW; Gore E
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1394-9. PubMed ID: 20646856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
    Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
    Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group.
    Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Perez CA
    Int J Radiat Oncol Biol Phys; 1991 Jan; 20(1):7-12. PubMed ID: 1847128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database.
    Komiya T; Chaaya G; Powell E
    Radiother Oncol; 2019 Feb; 131():75-80. PubMed ID: 30773190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
    Koul R; Rathod S; Dubey A; Bashir B; Chowdhury A
    Lung Cancer; 2018 Sep; 123():116-120. PubMed ID: 30089581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.